FDA says Potiga is effective as an add-on treatment for epilepsy

08/9/2010 | Wall Street Journal, The

Potiga, an experimental epilepsy drug by Valeant Pharmaceuticals International and GlaxoSmithKline, seems effective as an adjunctive treatment for partial-onset seizures in adults, but reports of urinary side effects are a concern, FDA reviewers said. An advisory panel is scheduled Wednesday to review the treatment.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA